VGK vs XBI
Vanguard FTSE Europe ETF vs SPDR S&P Biotech ETF
- • VGK has the lower expense ratio at 0.06% vs 0.35% for XBI.
- • VGK pays a higher dividend yield (2.95%).
Side-by-side metrics
| Metric | VGK | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.06% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.95% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $37.08B | $10.92B |
YTD return | 9.90% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.88 | 1.01 |
P/E ratio | 17.79 | — |
Last price | $89.42 | $156.41 |
Inception | — | — |
Issuer | Vanguard | State Street |
VGK top holdings
| ASML.AS | ASML Holding NV | 4.47% |
| HSBA.L | HSBC Holdings PLC | 2.19% |
| ROP.SW | Roche Holding AG Ordinary Shares new | 1.89% |
| SHEL.L | Shell PLC | 1.79% |
| NOVN.SW | Novartis AG Registered Shares | 1.72% |
| AZN.L | AstraZeneca PLC | 1.57% |
| NESN.SW | Nestle SA | 1.51% |
| SIE.DE | Siemens AG | 1.45% |
| SAP.DE | SAP SE | 1.32% |
| SAN.MC | Banco Santander SA | 1.29% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About VGK
VGK (Vanguard FTSE Europe ETF) is European developed-market equities. Managed by Vanguard, the fund carries $37.1B in assets under management, an expense ratio of 0.06%, a dividend yield of 2.95%. Its largest holding is ASML Holding NV (ASML.AS), which represents 4.5% of the portfolio. Real Estate is the fund's largest sector exposure at 1.4%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.